Compare WEX & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEX | INDV |
|---|---|---|
| Founded | 1983 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.7B |
| IPO Year | 2004 | 2014 |
| Metric | WEX | INDV |
|---|---|---|
| Price | $188.40 | $38.73 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $170.18 | N/A |
| AVG Volume (30 Days) | 795.6K | ★ 1.9M |
| Earning Date | 04-22-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.93 | ★ 8100.00 |
| EPS | ★ 5.33 | 1.67 |
| Revenue | ★ $2,660,800,000.00 | $1,239,000,000.00 |
| Revenue This Year | $4.93 | N/A |
| Revenue Next Year | $4.55 | N/A |
| P/E Ratio | $35.50 | ★ $21.86 |
| Revenue Growth | 1.24 | ★ 4.29 |
| 52 Week Low | $125.29 | $21.69 |
| 52 Week High | $191.38 | $42.81 |
| Indicator | WEX | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 75.32 | 47.41 |
| Support Level | $146.66 | $38.47 |
| Resistance Level | N/A | $41.83 |
| Average True Range (ATR) | 7.05 | 1.73 |
| MACD | 1.45 | -0.38 |
| Stochastic Oscillator | 92.06 | 55.43 |
WEX Inc is a commerce platform that provides seamlessly embedded, personalized payments solutions. The company operates three business segments: Mobility, Benefits, and Corporate Payments. Mobility segment, the top segment by revenue, provides fleet vehicle payment solutions, transaction processing, and information management services for commercial and government fleets. The Corporate Payments segment offers business-to-business payment processing and transaction monitoring services. The Benefits segment generates revenue from healthcare payment products and its consumer-directed software platform. Its prime end market is the United States of America.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).